We are live on ! Find out more
BFO

Boston Family Office Portfolio holdings

AUM $1.5B
1-Year Est. Return 11.68%
This Fund
S&P 500
This Quarter Est. Return
+15.63%
1 Year Est. Return
+11.68%
3 Year Est. Return
+44.44%
5 Year Est. Return
+55.04%
10 Year Est. Return
+258.3%
AUM
$925M
AUM Growth
+$121M
Cap. Flow
-$1.06M
Cap. Flow %
-0.11%
Top 10 Hldgs %
22.31%
Holding
255
New
7
Increased
77
Reduced
98
Closed
5

Top Buys

Rank Stock Value
1
APD icon
Air Products & Chemicals
APD
+$6.4M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$2.73M
3
CVS icon
CVS Health
CVS
+$2.43M
4
MSFT icon
Microsoft
MSFT
+$2.14M
5
V icon
Visa
V
+$1.6M

Top Sells

Rank Stock Value
1
LIN icon
Linde
LIN
+$7.75M
2
CELG
Celgene Corp
CELG
+$5.4M
3
AL
Air Lease Corp
AL
+$2.84M
4
AMT icon
American Tower
AMT
+$1.93M
5
KMI icon
Kinder Morgan
KMI
+$1.36M

Sector Composition

Rank Sector Weight
1 Healthcare 16.89%
2 Technology 16.36%
3 Industrials 11.15%
4 Consumer Staples 8.91%
5 Financials 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROP icon
26
Roper Technologies
ROP
$39.3B
$10.7M 1.16%
31,272
-234
-0.7% -$71K
XOM icon
27
ExxonMobil
XOM
$642B
$10.7M 1.15%
132,158
-5,057
-4% -$386K
SYK icon
28
Stryker
SYK
$129B
$10.5M 1.14%
53,287
+1,118
+2% +$201K
GOOG icon
29
Alphabet (Google) Class C
GOOG
$4.36T
$10.5M 1.13%
178,760
+9,140
+5% +$513K
APD icon
30
Air Products & Chemicals
APD
$66.8B
$10.4M 1.12%
54,420
+37,193
+216% +$6.4M
DLTR icon
31
Dollar Tree
DLTR
$24.9B
$10.1M 1.09%
96,132
-1,475
-2% -$145K
VZ icon
32
Verizon
VZ
$195B
$10.1M 1.09%
170,128
+281
+0.2% +$15.9K
TMO icon
33
Thermo Fisher Scientific
TMO
$214B
$10M 1.08%
36,618
+5,029
+16% +$1.25M
GIS icon
34
General Mills
GIS
$19.3B
$9.89M 1.07%
191,125
-2,350
-1% -$106K
RTN
35
DELISTED
Raytheon Company
RTN
$9.55M 1.03%
52,477
+4,707
+10% +$821K
NEE icon
36
NextEra Energy
NEE
$176B
$8.91M 0.96%
184,304
+1,444
+0.8% +$66K
PEP icon
37
PepsiCo
PEP
$189B
$8.9M 0.96%
72,590
-3,145
-4% -$358K
AFL icon
38
Aflac
AFL
$64.5B
$8.63M 0.93%
172,645
-1,144
-0.7% -$55.1K
ABT icon
39
Abbott
ABT
$187B
$8.48M 0.92%
106,027
-1,012
-0.9% -$75.3K
TEL icon
40
TE Connectivity
TEL
$62.3B
$8.25M 0.89%
102,151
-598
-0.6% -$48.2K
MRK icon
41
Merck
MRK
$317B
$8.06M 0.87%
101,631
-5,308
-5% -$397K
QQQ icon
42
Invesco QQQ Trust
QQQ
$479B
$7.5M 0.81%
41,759
+82
+0.2% +$13.9K
DHR icon
43
Danaher
DHR
$141B
$7.15M 0.77%
61,053
-1,455
-2% -$149K
CVS icon
44
CVS Health
CVS
$123B
$7.1M 0.77%
131,685
+39,358
+43% +$2.43M
MCD icon
45
McDonald's
MCD
$196B
$7.09M 0.77%
37,321
-967
-3% -$175K
MMM icon
46
3M
MMM
$93.2B
$6.99M 0.76%
40,250
-98
-0.2% -$16.5K
GILD icon
47
Gilead Sciences
GILD
$162B
$6.94M 0.75%
106,713
-2,091
-2% -$139K
ABBV icon
48
AbbVie
ABBV
$431B
$6.04M 0.65%
74,963
-1,366
-2% -$112K
SPGI icon
49
S&P Global
SPGI
$119B
$5.96M 0.64%
28,310
-270
-0.9% -$52.3K
IDXX icon
50
Idexx Laboratories
IDXX
$46.5B
$5.92M 0.64%
26,492
+1,373
+5% +$283K
1
2
3 4 5

Similar funds

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return
SGM
Seven Grand Managers Bronxville, New York $1.5B AUM 57.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Boston Family Office's Q1 2019 Portfolio in Review

As of Q1 2019, Boston Family Office held 255 positions worth $925M, up 15% from $804M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Trading was light in Q1 2019: portfolio turnover was 4.7%. Boston Family Office opened 7 new positions and exited 5, leaving the 255-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Technology and Industrials.

  • Boston Family Office's largest Q1 2019 buy was Enanta Pharmaceuticals: 2,750 shares worth $263K.
  • Boston Family Office added most to Air Products & Chemicals in Q1 2019, an estimated $6.4M increase.
  • Boston Family Office's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $5.4M.
  • Boston Family Office fully exited Linde in Q1 2019, selling an estimated $7.75M.
  • Boston Family Office's ten largest holdings make up 22% of its $925M portfolio in Q1 2019.
  • Boston Family Office opened 7 new positions and closed 5 in Q1 2019.
  • Boston Family Office's portfolio value rose 15% quarter-over-quarter to $925M.

Based on Boston Family Office's 13F filing for Q1 2019, filed 9 May 2019.